pharmaphorum

OCTOBER 12, 2022

Shares in Moderna were ticking upwards today after Merck & Co took up an option on a personalised RNA-based cancer vaccine with a payment of $250 million. As we all know, cancer vaccines have had a rough history. The post Merck gets on board with Moderna cancer vaccine in $250m deal appeared first on.

Vaccine 105

Vaccine Vaccination Gene Sequencing RNA 105

BioSpace

AUGUST 24, 2021

The development of COVID-19 vaccines, which took only months from the initial gene sequencing to the time shots were in arms, was the biggest story of 2020 alongside the pandemic itself.

Gene Sequencing 90

Gene Sequencing Gene Vaccine Vaccination 90

pharmaphorum

DECEMBER 14, 2022

The mRNA technology that was deployed so effectively in vaccines against COVID-19 has now been found to offer similar promise against cancer, according to Merck & Co and Moderna. The vaccine primes the immune system to attack the tumour cells, while Keytruda blocks an immunological ‘brake’ that protects the cancer.

Vaccine 98

Vaccine Vaccination Trials Gene Sequencing 98

pharmaphorum

JANUARY 5, 2023

The company develops mRNA therapeutics and vaccines , and the move will enable it to utilise the synthetic biology and enzyme tech of 2018-founded Japanese company OriCiro, which develops cell-free DNA synthesis and amplification technologies, and thereby expand Moderna’s portfolio. Biotech Moderna, Inc. and OriCiro Genomics K.K.

Gene Sequencing 97

Gene Sequencing DNA Vaccine Vaccination 97

pharmaphorum

OCTOBER 1, 2021

It also won a £113 million contract to provide rapid saliva-based COVID-19 testing services to the NHS, although that was ended early by the UK government in the summer as demand fell due to vaccinations. billion.

Marketing 52

Marketing Genomics Genome Business Development 52

Roots Analysis

OCTOBER 16, 2023

DNA and Gene Cloning involves the isolation of a DNA sequence of any species ( often a gene ) and its insertion into a vector to enable growth without any alteration in the original DNA sequence. These clones can be manipulated and mutated in vitro to alter the expression and function of a protein.

DNA 40

DNA Gene Protein In-Vitro 40

pharmaphorum

MAY 18, 2021

Canadian biotech Medicago has the data it was hoping for from a phase 2 trial of its COVID-19 vaccine, partnered with GlaxoSmithKline, and is now hoping to have phase 3 data available “by early summer.” The purified vaccine is administered alongside GSK’s pandemic adjuvant to boost the immune response.

Vaccine 64

Vaccine Vaccination Immune Response Gene Sequencing 64